RJA
PAVM icon

Raymond James & Associates’s PAVmed PAVM Stock Holding History

Raymond James & Associates’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-306
Closed -$40.6K – 3917
2023
Q3 		$40.6K Buy
306
+233
+319% +$36.1K ﹤0.01% 3691
2023
Q2 		$13.5K Hold
73
– – ﹤0.01% 3796
2023
Q1 		$12.3K Hold
73
– – ﹤0.01% 3829
2022
Q4 		$15.9K Buy
73
+49
+204% +$18.5K ﹤0.01% 3817
2022
Q3 		$9K Hold
24
– – ﹤0.01% 3865
2022
Q2 		$10K Sell
24
-4
-14% -$1.93K ﹤0.01% 3936
2022
Q1 		$17K Sell
28
-11
-28% -$8.18K ﹤0.01% 4022
2021
Q4 		$43K Sell
39
-160
-80% -$348K ﹤0.01% 3967
2021
Q3 		$763K Buy
199
+105
+112% +$331K ﹤0.01% 2757
2021
Q2 		$270K Buy
+94
New +$222K ﹤0.01% 3504

Other funds holding PAVM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
XF
XML Financial Bethesda, Maryland $1.24B AUM 20.4% 1-Year Est. Return

Raymond James & Associates's PAVM Position: Q4 2023 in Review

Raymond James & Associates sold out of PAVmed (PAVM) in Q4 2023, closing a stake of 306 shares — an estimated $40.6K sold.

Raymond James & Associates first reported a position in PAVM in Q2 2021 and held it in 10 quarters. The position peaked at $763K in Q3 2021. 23 funds tracked by Wall St. Rank hold PAVM as of Q4 2023.

  • Raymond James & Associates reported no remaining PAVmed position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 306 PAVmed shares in Q4 2023, an estimated $40.6K.
  • Raymond James & Associates first reported a position in PAVmed in Q2 2021 and held it in 10 quarters.
  • Raymond James & Associates's PAVmed position peaked at $763K in Q3 2021.
  • 23 funds tracked by Wall St. Rank held PAVmed as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.